Results 31 to 40 of about 4,532 (195)

A Systematic Review on Disease‐Modifying Therapies in Parkinsonian Disorders

Clinical Pharmacology &Therapeutics, EarlyView.
Parkinsonian disorders, including Parkinson's disease, Lewy body dementia, multiple system atrophy, and progressive supranuclear palsy, are progressive neurodegenerative conditions with no treatment options to slow disease progression. This systematic review provides an overview of evidence of disease‐modifying therapies that have been evaluated in ...
Pepijn P.N.M. Eijsvogel, Lars M.G. Smits, Philip H.C. Kremer, Geert Jan Groeneveld   +3 more
wiley   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

The issue of the cardiovascular safety of dihydropyridines [PDF]

American Journal of Hypertension, 1996
This review describes aspects of the calcium channel blocker controversy as it relates to hypertensive and coronary artery disease patients. Much of the controversy has occurred because of off-label use of short-acting calcium channel blockers that were never approved or recommended for use in patients with hypertension or acute myocardial infarction ...
openaire   +2 more sources

Synthesis of 2‐Aza‐Bicyclo[4.3.0]nonane Derivatives Related to the Camporidines via Intramolecular [3+2]‐Cycloaddition

European Journal of Organic Chemistry, EarlyView.
The intramolecular nitrile oxide olefin [3 + 2]‐cycloaddition offers a reliable entry toward 2‐aza‐bicyclo[4.3.0]‐nonanes, a substructure found in several bioactive piperidine alkaloids. The required oxime precursors were prepared in non‐racemic form by Ir‐catalyzed asymmetric allylation and ring‐closing metathesis.
Alicia Köcher, Tobias Wilczek, Nora Katharina Korber, Jörg-Martin Neudörfl, Bernd Goldfuss, Hans-Günther Schmalz   +5 more
wiley   +1 more source

4-Aryldihydropyrimidines via the Biginelli Condensation: Aza-Analogs of Nifedipine-Type Calcium Channel Modulators

Molecules, 1998
Recent results from the author's laboratory in the area of dihydropyrimidine chemistry are summarized.
C. Oliver Kappe
doaj   +1 more source

Gold(I)‐Mediated Reactivity of Allenes With Mesoionic Nucleophiles: A Computational Exploration

European Journal of Organic Chemistry, EarlyView.
The regioselective gold(I)‐mediated reactivity of allenes with mesoionic nucleophiles has been evaluated through computational analysis of the mechanisms involved. Instead of typical (3 + 2) pathways, sydnones and münchnones favour the formal (3 + 3) cyclizations affording substituted dihydropyridines.
Eduardo Garcia‐Padilla, Feliu Maseras
wiley   +1 more source

Crystal structure of 2-amino-4-(4-chlorophenyl)-1-(4-methylphenyl)-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carbonitrile

Acta Crystallographica Section E: Crystallographic Communications, 2015
In the title compound, C23H20ClN3O, each of the cyclohexene and 1,4-dihydropyridine rings of the 1,4,5,6,7,8-hexahydroquinoline ring system adopts a twisted-boat conformation. The dihedral angle between the two benzene rings is 11.52 (7)°. In the crystal,
Shaaban K. Mohamed, Mehmet Akkurt, Jerry P. Jasinski, Omyma A. A. Abd Allah, Mustafa R. Albayati   +4 more
doaj   +1 more source

Inherited metabolic epilepsies–established diseases, new approaches

Epilepsia Open, EarlyView.
Abstract Inherited metabolic epilepsies (IMEs) represent the inherited metabolic disorders (IMDs) in which epilepsy is a prevailing component, often determining other neurodevelopmental outcomes associated with the disorder. The different metabolic pathways affected by individual IMEs are the basis of their rarity and heterogeneity.
Itay Tokatly Latzer, Phillip L. Pearl
wiley   +1 more source

Revisiting the Association Between Calcium Channel Blockers and Parkinson's Disease in the E3N Cohort

Movement Disorders, EarlyView.
Abstract Background Previous studies on calcium channel blockers (CCBs) and Parkinson's disease (PD) risk reached conflicting conclusions. Objectives We examined the relationship between CCBs and PD in the E3N cohort of French women followed for 15 years (2004–2018), while taking into account the potential for reverse causation.
Emilie Moutard, Agnès Fournier, Émeline Courtois, Fanny Artaud, Pascale Tubert‐Bitter, Emmanuel Roze, Ismaïl Ahmed, Anne C.M. Thiébaut, Alexis Elbaz, Thi Thu Ha Nguyen   +9 more
wiley   +1 more source

DIHYDROPYRIDINE CALCIUM ANTAGONISTS: DATA OF EVIDENCE BASED MEDICINE AND RECOM-MENDATIONS ON PRACTICAL USE

Рациональная фармакотерапия в кардиологии, 2015
The classification of calcium antagonists is presented. There were considered the results of large randomized trials, which were devoted to study of influence of dihydropyridine calcium antagonists on the risk of cardiovascular complications.
S. Y. Martsevich
doaj   +1 more source